nach oben

Current Cardiology Reports

Erschienen in:

04.03.2024 | Management of Acute Coronary Syndromes (H Jneid, Section Editor)

Updates on Non-Statin LDL-Lowering Therapy

verfasst von: Amer Abdulla, Mostafa Shalaby, Paul Kumfa, Muhammad Raja, Joseph Allencherril, Tareq Abu Sharifeh

Erschienen in: Current Cardiology Reports | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

There is ample evidence of the benefits and safety of low-density lipoprotein (LDL)-lowering therapies in the prevention of atherosclerotic cardiovascular disease. While statins remain the first-line agent for LDL reduction, several new therapies are now available. This narrative review provides an overview of currently available non-statin LDL-lowering agents, specifically mechanisms of action and data on efficacy and safety. It also discusses recommendations on their use in clinical practice.

Recent Findings

Ezetimibe, PCSK9 inhibitors, and bempedoic acid have proven safe and efficacious in reducing cardiovascular events in large randomized controlled trials. Inclisiran is a promising agent that suppresses PCSK9 mRNA translation and is currently under investigation in a large clinical outcomes randomized controlled trial assessing its effect on clinical outcomes.

Summary

Expert consensus advocates for lower LDL targets in higher risk patients and escalation to or a combination of non-statin therapies as needed to achieve these goals.

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.CrossRef

• Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637–43. This large meta-analysis showed patients older than 75 years of age also benefit from LDL-reducing agents like those younger than 75 years of age.CrossRefPubMedPubMedCentral

Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–9.CrossRefPubMed

Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144–53.CrossRefPubMed

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81.CrossRefPubMed

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.PubMed

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.CrossRefPubMed

Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–8.CrossRefPubMed

Myocardial Infarction Genetics Consortium Investigators, Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072–82.CrossRef

10.

Ezetimibe FDA Approval Letter. 2002 [cited 2023 Feb 7]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_Approv.pdf.

11.

Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251–61.CrossRefPubMed

12.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.CrossRefPubMed

13.

Evolocumab FDA Approval Letter [Internet]. 2015 [cited 2023 Jun 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125522Orig1s000ltr.pdf.

14.

Alirocumab FDA Approval Letter [Internet]. 2015 [cited 2023 Jun 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125559Orig1s000ltr.pdf.

15.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–22.CrossRefPubMed

16.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097–107.CrossRefPubMed

17.

Evolocumab Package Insert [Internet]. [cited 2023 Dec 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125522orig2s000lbl.pdf.

18.

Alirocumab Package Insert [Internet]. [cited 2023 Dec 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125559s002lbl.pdf.

19.

Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, et al. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017;376(16):1517–26.CrossRefPubMed

20.

Bempedoic Acid FDA Approval Letter [Internet]. 2020 [cited 2023 Jun 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211616Orig1s000ltr.pdf.

21.

•• Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353–64. This was a landmark randomized controlled trial that demonstrated bempedoic acid, when compared to placebo, reduced major adverse cardiovascular events in patients unable or unwilling to take a statin.CrossRefPubMed

22.

Inclisiran FDA Approval Letter. 2021 [cited 2023 Jun 7]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214012Orig1s000ltr.pdf.

23.

Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–40.CrossRefPubMed

24.

•• Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19. This randomized controlled trial demonstrated the powerful and safe LDL-reducing capability of inclisiran.CrossRefPubMed

25.

•• Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol. 2022;80(14):1366–418. This expert consensus pathway document provided guidance on the use of recently FDA-approved non-statin agents.CrossRef

26.

Evinacumab FDA Approval Letter [Internet]. 2021 [cited 2023 Jun 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761181Orig1s000ltr.pdf.

27.

Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–20.CrossRefPubMed

28.

Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307–19.CrossRefPubMed

29.

Lomitapide FDA Approval Letter [Internet]. 2012 [cited 2023 May 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000Approv.pdf.

30.

Kolovou G, Diakoumakou O, Kolovou V, Fountas E, Stratakis S, Zacharis E, et al. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2020;27(2):157–65.CrossRefPubMed

31.

Cuchel M, Meagher EA, du Toit TH, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40–6.CrossRefPubMed

32.

Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356(2):148–56.CrossRefPubMed

33.

Mipomersen FDA Approval Letter [Internet]. 2013 [cited 2023 May 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203568Orig1s000Approv.pdf.

34.

Li N, Li Q, Tian XQ, Qian HY, Yang YJ. Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2014;14(5):367–76.CrossRefPubMed

35.

Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62(23):2178–84.CrossRefPubMed

36.

The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351–64.CrossRef

37.

Parhofer KG. Apheresis: What Should a Clinician Know? Curr Atheroscler Rep. 2023;25(3):77–83.CrossRefPubMedPubMedCentral

38.

Liposorber LA-15 System FDA Approval [Internet]. 2019 [cited 2023 May 7]. Available from: https://www.kmp-us.com/pdf/Approval%20Letter%20from%20FDA%20lowering%20LDL%20to%20100.pdf.

39.

Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017;377(7):633–43.CrossRefPubMed

40.

• Patti G, Spinoni EG, Grisafi L, Mehran R, Mennuni M. Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):138–47. This large meta-analysis provided evidence that reducing LDL <40 mg/dL was not associated with increased adverse effects when compared to higher levels.CrossRefPubMed

41.

Bateman BT, Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, et al. Statins and congenital malformations: cohort study. BMJ. 2015;17(350): h1035.CrossRef

42.

FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins [Internet]. 2021 [cited 2023 Jun 7]. Available from: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy.

43.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.CrossRefPubMedPubMedCentral

44.

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–407.CrossRefPubMed

45.

Atorvastatin Package Insert [Internet]. [cited 2023 Dec 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020702s073lbl.pdf.

46.

Ramkumar S, Raghunath A, Raghunath S. Statin therapy: Review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631–9.PubMedPubMedCentral

47.

Ezetimibe Package Insert [Internet]. [cited 2023 Dec 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021445s042lbl.pdf.

48.

Bempedoic Acid Package Insert. [cited 2023 Dec 31]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf.

49.

Inclisiran Package Insert. [cited 2023 Dec 31]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf.

50.

Evinacumab Package Insert [Internet]. [cited 2023 Dec 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761181s001lbl.pdf.

51.

Lomitapide Package Insert [Internet]. [cited 2023 Dec 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203858s000lbl.pdf.

52.

Mipomersen Package Insert [Internet]. [cited 2023 Dec 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203568s011lbl.pdf.

53.

Lent-Schochet D, Jialal I. Antilipemic Agent Bile Acid Sequestrants. 2023.

54.

McGowan MP. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol–the role of LDL-apheresis. J Clin Lipidol. 2013;7(3 Suppl):S21–6.CrossRefPubMed

Titel: Updates on Non-Statin LDL-Lowering Therapy
verfasst von: Amer Abdulla
Mostafa Shalaby
Paul Kumfa
Muhammad Raja
Joseph Allencherril
Tareq Abu Sharifeh
Publikationsdatum: 04.03.2024
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 4/2024
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-024-02028-3

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Updates on Non-Statin LDL-Lowering Therapy

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Mechanical Circulatory Support for High-Risk Percutaneous Coronary Intervention

Open Surgical Therapy for Peripheral Artery Disease

The Global Epidemic of Metabolic Fatty Liver Disease

Update on the Role of Colchicine in Cardiovascular Disease

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie